[HTML][HTML] Inhibitor of nonhomologous end joining can inhibit proliferation of diffuse large B-cell lymphoma cells and potentiate the effect of ionization radiation
V Gopalakrishnan, G Radha… - Journal of Radiation …, 2018 - journals.lww.com
Aim: Diffuse large B-cell lymphoma (DLBCL) is the most common and aggressive type of
non-Hodgkin's lymphoma that accounts for~ 40% of all lymphomas. DLBCL is considered to …
non-Hodgkin's lymphoma that accounts for~ 40% of all lymphomas. DLBCL is considered to …
Inhibitor of nonhomologous end joining can inhibit proliferation of diffuse large B-Cell lymphoma cells and potentiate the effect of ionization radiation.
V Gopalakrishnan, G Radha, S Raghavan… - Journal of Radiation …, 2018 - go.gale.com
Aim: Diffuse large B-cell lymphoma (DLBCL) is the most common and aggressive type of
non-Hodgkin's lymphoma that accounts for~ 40% of all lymphomas. DLBCL is considered to …
non-Hodgkin's lymphoma that accounts for~ 40% of all lymphomas. DLBCL is considered to …
Inhibitor of nonhomologous end joining can inhibit proliferation of diffuse large b-cell lymphoma cells and potentiate the effect of ionization radiation
V Gopalakrishnan, B Choudhary, G Radha… - Journal of Radiation …, 2017 - inis.iaea.org
[en] Diffuse large B-cell lymphoma (DLBCL) is the most common and aggressive type of non-
Hodgkin's lymphoma that accounts for∼ 40% of all lymphomas. DLBCL is considered to be …
Hodgkin's lymphoma that accounts for∼ 40% of all lymphomas. DLBCL is considered to be …
Inhibitor of nonhomologous end joining can inhibit proliferation of diffuse large b-cell lymphoma cells and potentiate the effect of ionization radiation
V Gopalakrishnan, B Choudhary, G Radha… - Journal of Radiation …, 2018 - inis.iaea.org
[en] Diffuse large B-cell lymphoma (DLBCL) is the most common and aggressive type of non-
Hodgkin's lymphoma that accounts for∼ 40% of all lymphomas. DLBCL is considered to be …
Hodgkin's lymphoma that accounts for∼ 40% of all lymphomas. DLBCL is considered to be …